Nanjing Hicin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300584.SZ

Nanjing Hicin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2023: 7.01%

Nanjing Hicin Pharmaceutical Co., Ltd. Net Income Margin is 7.01% for the year ending December 31, 2023, a 13.78% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Nanjing Hicin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2022 was 6.16%, a -87.53% change year over year.
  • Nanjing Hicin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2021 was 49.43%, a 532.16% change year over year.
  • Nanjing Hicin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2020 was 7.82%, a -25.67% change year over year.
  • Nanjing Hicin Pharmaceutical Co., Ltd. Net Income Margin for the year ending December 31, 2019 was 10.52%, a -10.01% change year over year.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 300584.SZ

Nanjing Hicin Pharmaceutical Co., Ltd.

CEO Mr. Yuping Cao
IPO Date Jan. 12, 2017
Location China
Headquarters No.1 Hengfa Road
Employees 553
Sector Healthcare
Industries
Description

Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.

StockViz Staff

February 4, 2025

Any question? Send us an email